TRCT
CMTA

Tower Research Capital (TRC)’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Tower Research Capital (TRC)’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,165
Closed -$30K – 4724
2019
Q1 		$30K Sell
1,165
-1,632
-58% -$30.5K ﹤0.01% 2057
2018
Q4 		$33K Buy
2,797
+2,335
+505% +$29K ﹤0.01% 1589
2018
Q3 		$5K Sell
462
-1,357
-75% -$14.3K ﹤0.01% 3161
2018
Q2 		$24K Sell
1,819
-305
-14% -$4.94K ﹤0.01% 2339
2018
Q1 		$32K Buy
+2,124
New +$34.6K ﹤0.01% 1945
2017
Q4 		– Sell
-200
Closed -$3K – 4343
2017
Q3 		$3K Buy
+200
New +$3.27K ﹤0.01% 3523

Tower Research Capital (TRC)'s CMTA Position: Q2 2019 in Review

Tower Research Capital (TRC) sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 1,165 shares — an estimated $30K sold.

Tower Research Capital (TRC) first reported a position in CMTA in Q3 2017 and held it in 6 quarters. The position peaked at $33K in Q4 2018. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

  • Tower Research Capital (TRC) reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,165 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $30K.
  • Tower Research Capital (TRC) first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Clementia Pharmaceuticals Inc. position peaked at $33K in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2019, filed 13 Aug 2019.